Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus

Background: Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular (CV) disease. In patients with T2D and established CV disease, selective inhibitors of sodium–glucose cotransporter 2 (SGLT2) have been shown to decrease CV and all-cause mortality, and heart failure (HF) admiss...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Sharmaine Thirunavukarasu, Louise AE Brown, Amrit Chowdhary, Nicholas Jex, Peter Swoboda, John P Greenwood, Sven Plein, Eylem Levelt
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	SAGE Publishing 2021-06-01
Ráidu:	Diabetes & Vascular Disease Research
Liŋkkat:	https://doi.org/10.1177/14791641211021585
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!